Zhijun Medical expands therapeutics supply across Southeast Asia

The firm eyes localisation and epidemic readiness as demand rises for vaccines and blood products across the region.

Shenzhen Zhijun Medical and Pharmaceutical Trading Co., Ltd. is intensifying its focus on Southeast Asia’s healthcare sector, targeting urgent gaps in vaccine access and biological supply. Speaking at The Health Industry Series – ASEAN in Malaysia, Deputy Minister of International Business Kristy Li highlighted epidemic response and localisation as core priorities.

“In the vaccine sector, the major phrase is how to really react to those epidemic issues in different regions,” said Li. “During COVID, the whole world was worried about how to get the right vaccine… so we reacted quickly and developed our first inactivated vaccine and supplied it to international markets.”

Li added that beyond pandemic preparedness, Zhijun Medical’s products—ranging from vaccines to blood-based therapeutics—are critical in natural disasters such as earthquakes. “We can respond quickly and supply those life-saving materials to different sectors and help save lives,” she said.

The firm sees untapped growth opportunities in localising vaccine and blood product manufacturing. “Countries [in Southeast Asia] are facing challenges in local supply,” said Li. “We are interested in working with local partners to do localisation of biologicals… and to build up capacity in the region.”

To support this goal, Zhijun Medical is banking on its cross-border experience. “We work with external partners in the production and research development of vaccines, blood products, antibodies, and diagnostics.”